Acadia Healthcare
ACHC
$32.50
-5.82%
Acadia Healthcare Company, Inc. is a leading provider of behavioral healthcare services in the United States, operating acute inpatient psychiatric facilities, specialty treatment centers, and residential treatment centers. As one of the largest pure-play behavioral health platforms, it holds a distinct competitive position in a fragmented industry with strong demand tailwinds from rising mental health awareness and regulatory support. The current investor narrative centers on the company's dramatic turnaround story, as it recovers from a massive goodwill impairment charge in Q4 2025 that wiped out earnings, while recent operational improvements and analyst upgrades signal renewed confidence in its growth trajectory and margin recovery.…
ACHC
Acadia Healthcare
$32.50
Related headlines
Investment Opinion: Should I buy ACHC Today?
Rating: Hold. Acadia Healthcare is a speculative turnaround play with deep value characteristics but significant execution risk. The consensus analyst rating is Buy (mean 2.0), with an average target of $32.21, implying 6.7% downside from the current price of $34.51. The thesis hinges on whether the operational improvements seen in Q1 2026 (revenue growth 7.6%, operating margin 10.1%) can be sustained and translate into positive free cash flow.
Supporting evidence includes: (1) trailing P/S of 0.39x, a deep discount to historical levels (2.5x-10.9x), (2) revenue growth accelerating from 5.8% to 7.6% over the past three quarters, (3) gross margin improving to 16.5% from 11.7% in Q4 2025, and (4) forward P/E of 19.64x, which is reasonable given expected EPS growth of over 100% (PEG 0.002). However, the negative FCF and impairment overhang temper the bullish case.
Key risks that could invalidate the thesis: (1) failure to achieve positive free cash flow within the next 12 months, (2) further goodwill impairments or regulatory setbacks, and (3) a broader market downturn compressing growth stock multiples. This Hold would upgrade to Buy if the company reports positive FCF and operating margin above 12%, or downgrade to Sell if revenue growth decelerates below 5% or if another impairment is announced. Overall, the stock appears undervalued on a P/S and P/B basis relative to its history, but the negative FCF and impairment risk justify a cautious stance.
Sign up to view all
ACHC 12-Month Price Forecast
The AI assessment is bullish with medium confidence. The key factors supporting this stance are the accelerating revenue growth (7.6% YoY), deeply discounted valuation (P/S 0.39x), and reasonable forward P/E (19.64x) given the expected earnings rebound. However, the negative free cash flow and high short interest temper confidence. The base case is most likely (45% probability), with the stock trading near the average target. An upgrade to high confidence would require positive FCF and sustained margin improvement; a downgrade would occur if revenue growth decelerates or another impairment is announced.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Acadia Healthcare's 12-month outlook, with a consensus price target around $32.21 and implied upside of -0.9% versus the current price.
Average Target
$32.21
0 analysts
Implied Upside
-0.9%
vs. current price
Analyst Count
—
covering this stock
Price Range
$13 - $40
Analyst target range
Acadia Healthcare is covered by 14 analysts, with a consensus recommendation of 'Buy' (mean rating 2.0 on a 1-5 scale where 1 is Strong Buy). The average price target is $32.21, which implies a 6.7% downside from the current price of $34.51, indicating that the stock has already surpassed the average target. The distribution shows 10 Buy/Overweight ratings, 3 Hold/Neutral, and 1 Sell, reflecting a predominantly bullish sentiment. Recent upgrades from Jefferies (Hold to Buy) and reaffirmations from TD Cowen, Keybanc, and UBS underscore growing confidence in the turnaround. The target range spans from a low of $13.00 to a high of $40.00, representing a wide spread of 208% from low to high, signaling high uncertainty about the company's future. The high target of $40.00 assumes successful execution of margin recovery and continued revenue growth, while the low target of $13.00 prices in potential setbacks such as regulatory headwinds or failure to sustain operational improvements. The fact that the current price exceeds the average target suggests that the market is more optimistic than the consensus, possibly anticipating further positive catalysts.
Drowning in data?
Find the real signal!
Bulls vs Bears: ACHC Investment Factors
Acadia Healthcare presents a high-risk, high-reward turnaround story. The bull case rests on accelerating revenue growth (7.6% YoY), improving margins (operating margin 10.1%), and deep value metrics (P/S 0.39x, P/B 0.66x) that suggest the market is discounting a recovery. However, the bear case highlights negative free cash flow (-$291.8M TTM), a massive goodwill impairment that wiped out earnings, and the stock trading above the average analyst target ($32.21). The single most important tension is whether the operational improvements are sustainable: if margins continue to recover and FCF turns positive, the stock could re-rate significantly; if the turnaround stalls, the stock could fall back toward the low analyst target of $13.00. Currently, the bull side has stronger evidence given the recent earnings beat and analyst upgrades, but the high short interest and fund exit warrant caution.
Bullish
- Revenue Growth Accelerating: Q1 2026 revenue grew 7.6% YoY to $828.8M, accelerating from 6.6% in Q4 2025 and 5.8% in Q3 2025, driven by higher patient volumes and favorable payer mix.
- Deep Value on P/S and P/B: Trailing P/S of 0.39x and P/B of 0.66x are near historical lows, suggesting the market is pricing in a worst-case scenario that may not materialize, offering a potential margin of safety.
- Strong Momentum and Analyst Upgrades: Stock surged 58.7% over the past year and 38.3% in the past month, with recent upgrades from Jefferies (Hold to Buy) and reaffirmations from TD Cowen, Keybanc, and UBS signaling growing confidence.
- Improving Operating Margins: Operating margin recovered to 10.1% in Q1 2026 from 5.8% in Q4 2025 (excluding impairment), and gross margin improved to 16.5% from 11.7%, indicating operational turnaround is gaining traction.
Bearish
- Negative Free Cash Flow: Free cash flow was -$15.0M in Q1 2026 and -$291.8M TTM, primarily due to heavy capex for facility expansions, raising concerns about capital allocation and financial sustainability.
- Massive Goodwill Impairment: A $1.2B goodwill impairment in Q4 2025 caused a net loss of $1.18B and negative net margin of -143.3%, eroding shareholder equity and signaling past overpayment for acquisitions.
- Stock Above Average Analyst Target: Current price of $34.51 exceeds the average analyst target of $32.21, implying 6.7% downside and suggesting the market may be overly optimistic relative to consensus.
- High Short Interest and Fund Exit: Short ratio of 6.83 days indicates elevated bearish sentiment, and a major fund completely exited a $13M stake in March 2026, signaling deep concerns about the turnaround.
ACHC Technical Analysis
Acadia Healthcare is in a powerful sustained uptrend, with the stock surging 58.7% over the past year compared to the S&P 500's 16.5% gain. The current price of $34.51 sits at 96.3% of its 52-week range ($11.43–$35.83), indicating strong momentum and near-term overextension but also reflecting robust investor conviction. This positioning near the highs suggests the market is pricing in continued operational improvement, though it also raises the risk of a mean-reverting pullback. Short-term momentum is exceptionally strong, with the stock gaining 38.3% in the past month and 26.0% over the past three months, far outpacing the S&P 500's 0.8% and 3.5% returns, respectively. This acceleration from the 1-year trend signals a breakout phase, likely driven by the Q1 2026 earnings beat and positive analyst revisions. The relative strength index (RSI) is not explicitly provided, but the rapid price appreciation suggests it may be in overbought territory, warranting caution for new entries. The 52-week low of $11.43 provides a clear support level, while the 52-week high of $35.83 acts as immediate resistance. A breakout above $35.83 would confirm the uptrend continuation and open the door to further upside, while a breakdown below recent support near $30 could signal a trend reversal. The stock's beta of 0.64 indicates it is 36% less volatile than the market, which is unusual for a healthcare facility operator but implies lower systematic risk and may attract defensive-oriented investors.
Beta
0.64
0.64x market volatility
Max Drawdown
-57.1%
Largest decline past year
52-Week Range
$11-$36
Price range past year
Annual Return
+46.0%
Cumulative gain past year
| Period | ACHC Return | S&P 500 |
|---|---|---|
| 1m | +18.5% | +1.4% |
| 3m | +17.8% | +3.9% |
| 6m | +141.8% | +6.3% |
| 1y | +46.0% | +16.0% |
| ytd | +127.4% | +8.4% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
ACHC Fundamental Analysis
Revenue has shown steady growth, with Q1 2026 revenue of $828.8 million representing 7.6% year-over-year growth, accelerating from the 6.6% growth in Q4 2025 and 5.8% in Q3 2025. The company's revenue trajectory is clearly improving, driven by higher patient volumes and favorable payer mix in its acute inpatient psychiatric facilities, which generate the majority of revenue. This consistent growth supports the investment case that Acadia is benefiting from secular demand for behavioral health services. Profitability has been highly volatile due to a massive goodwill impairment charge of $1.2 billion in Q4 2025, which caused a net loss of $1.18 billion and a negative net margin of -143.3% for that quarter. Excluding this non-cash charge, operating profitability is improving: Q1 2026 net income was $4.1 million (net margin 0.5%), compared to a loss in Q4 2025, and gross margin improved to 16.5% from 11.7% in Q4 2025. The company's operating margin of 10.1% in Q1 2026 is still below the 14.0% in Q3 2025 but shows recovery from the trough. The balance sheet shows moderate leverage with a debt-to-equity ratio of 1.36 and a current ratio of 1.55, indicating adequate liquidity. However, free cash flow remains negative at -$15.0 million in Q1 2026 and -$291.8 million over the trailing twelve months, primarily due to heavy capital expenditures for facility expansions. Return on equity is deeply negative at -56.6% due to the impairment, but the underlying business generates positive operating cash flow ($61.5 million in Q1 2026), suggesting the negative FCF is a growth investment phase rather than a sign of distress.
Quarterly Revenue
$828802000.0B
2026-03
Revenue YoY Growth
+7.6%
YoY Comparison
Gross Margin
16.5%
Latest Quarter
Free Cash Flow
$-291788000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is ACHC Overvalued?
Given that net income is negative on a trailing basis (EPS -$0.86), the trailing P/E ratio of -1.17 is not meaningful. Therefore, we use the price-to-sales (P/S) ratio as the primary valuation metric. The trailing P/S ratio is 0.39, which is extremely low and suggests the market is pricing in significant earnings recovery. The forward P/E of 19.64 implies that analysts expect a sharp rebound in profitability, with the gap between trailing and forward metrics reflecting the anticipated normalization after the impairment charge. Compared to the industry average P/S ratio (not provided, but healthcare facilities typically trade at 1-2x sales), Acadia's P/S of 0.39 is a deep discount, likely due to the recent impairment and perceived risk. However, on a forward P/E basis, the 19.64x multiple is reasonable for a company with expected EPS growth of over 100% (PEG ratio of 0.002). Historically, Acadia's P/S ratio has ranged from 2.5x to 10.9x over the past five years, with the current 0.39x near the absolute bottom. This suggests the market is pricing in a worst-case scenario that may not materialize, presenting a potential value opportunity if the turnaround gains traction. The P/B ratio of 0.66 also indicates the stock is trading below book value, further supporting the value thesis.
PE
-1.2x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range 15x~31x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
-5.2x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: Acadia's balance sheet shows moderate leverage with a debt-to-equity ratio of 1.36, but the massive $1.2B goodwill impairment in Q4 2025 has severely damaged equity, leading to a negative ROE of -56.6%. Free cash flow remains deeply negative at -$291.8M TTM, primarily due to heavy capital expenditures for facility expansions. While operating cash flow was positive at $61.5M in Q1 2026, the negative FCF indicates the company is still in an investment phase that could strain liquidity if revenue growth slows. The current ratio of 1.55 provides some cushion, but the reliance on continued growth to justify the valuation is a key risk.
Market & Competitive Risks: The stock's beta of 0.64 suggests lower market correlation, but the behavioral healthcare industry faces regulatory risks and reimbursement changes. The stock has already surpassed the average analyst target of $32.21, implying limited upside from consensus and potential for a pullback if sentiment shifts. The high short ratio of 6.83 days indicates persistent bearish positioning, and a major fund's complete exit from a $13M stake in March 2026 signals institutional skepticism. Additionally, the wide analyst target range ($13-$40) reflects high uncertainty about the company's future.
Worst-Case Scenario: If the operational turnaround fails to materialize—due to regulatory headwinds, rising costs, or inability to sustain patient volumes—the stock could fall to the 52-week low of $11.43, representing a 66.9% decline from the current price of $34.51. This scenario would likely involve further impairment charges, negative earnings revisions, and analyst downgrades, pushing the stock toward the low target of $13.00. The historical max drawdown of -57.11% provides a reference for potential downside in a severe adverse scenario.
FAQ
The key risks are: (1) Financial risk: negative free cash flow of -$291.8M TTM and a debt-to-equity ratio of 1.36 could strain liquidity if revenue growth slows. (2) Operational risk: the $1.2B goodwill impairment in Q4 2025 highlights past overpayment for acquisitions and the potential for further write-downs. (3) Market risk: the stock has already surpassed the average analyst target of $32.21, and the high short ratio of 6.83 days indicates bearish sentiment. (4) Regulatory risk: changes in behavioral health reimbursement policies could impact revenue. The most severe risk is a failure of the turnaround, which could drive the stock down to the 52-week low of $11.43.
The 12-month outlook is mixed. The bull case (30% probability) targets $35.83-$40.00, driven by successful margin recovery and positive FCF. The base case (45% probability) sees the stock trading around $30-$35, with gradual improvement but limited upside. The bear case (25% probability) targets $13-$20 if the turnaround stalls. The most likely scenario is the base case, with the stock near the average analyst target of $32.21. Key assumptions include sustained revenue growth of 7-8% and operating margins stabilizing around 10%.
ACHC appears undervalued on a price-to-sales basis, with a trailing P/S of 0.39x, which is near the bottom of its historical range of 2.5x-10.9x. The price-to-book ratio of 0.66x also indicates the stock is trading below book value. However, the trailing P/E is negative (-1.17x) due to the impairment, making earnings-based valuation unreliable. On a forward P/E of 19.64x, the stock is reasonably priced given expected EPS growth of over 100% (PEG 0.002). Compared to the industry average P/S (typically 1-2x), ACHC is deeply discounted, suggesting the market is pricing in significant risk.
ACHC is a high-risk, high-reward investment. The stock offers deep value with a P/S of 0.39x and P/B of 0.66x, but the negative free cash flow (-$291.8M TTM) and massive goodwill impairment ($1.2B) introduce significant uncertainty. The analyst consensus is Buy, with an average target of $32.21, implying 6.7% downside from the current price of $34.51. For risk-tolerant investors with a long-term horizon, it could be a good buy if the turnaround gains traction; however, conservative investors may want to wait for evidence of positive FCF and sustained margin improvement before entering.
ACHC is better suited for long-term investment (2-3 years) given its turnaround nature and the time needed for operational improvements to materialize. The stock's beta of 0.64 indicates lower volatility than the market, but the high short interest and recent rapid price appreciation (38.3% in one month) suggest short-term trading risks. The company pays no dividend, so total return depends on price appreciation. A minimum holding period of 12-18 months is recommended to allow the turnaround to play out and for free cash flow to potentially turn positive.
